Our top pick for
Beginners

Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.
TELA Bio, Inc is a medical devices business based in the US. TELA Bio shares (TELA) are listed on the NASDAQ and all prices are listed in US Dollars. TELA Bio employs 89 staff and has a trailing 12-month revenue of around USD$17.4 million.
Our top pick for
Beginners
Our top pick for
Building a portfolio
Our top pick for
Mobile users
Latest market close | USD$16.38 |
---|---|
52-week range | USD$5.25 - USD$23.545 |
50-day moving average | USD$16.3443 |
200-day moving average | USD$15.3816 |
Wall St. target price | USD$20 |
PE ratio | N/A |
Dividend yield | N/A (0%) |
Earnings per share (TTM) | N/A |
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $16.38 from 2020-12-11
1 week (2021-01-06) | N/A |
---|---|
1 month (2020-12-13) | N/A |
3 months (2020-10-13) | N/A |
6 months (2020-07-13) | N/A |
1 year (2020-01-13) | N/A |
---|---|
2 years (2019-01-13) | N/A |
3 years (2018-01-13) | N/A |
5 years (2016-01-13) | N/A |
Revenue TTM | USD$17.4 million |
---|---|
Gross profit TTM | USD$9.6 million |
Return on assets TTM | -26.38% |
Return on equity TTM | -133.29% |
Profit margin | -158.16% |
Book value | $3.903 |
Market capitalisation | USD$236.7 million |
TTM: trailing 12 months
There are currently 143,379 TELA Bio shares held short by investors – that's known as TELA Bio's "short interest". This figure is 6.2% down from 152,797 last month.
There are a few different ways that this level of interest in shorting TELA Bio shares can be evaluated.
TELA Bio's "short interest ratio" (SIR) is the quantity of TELA Bio shares currently shorted divided by the average quantity of TELA Bio shares traded daily (recently around 18103.409090909). TELA Bio's SIR currently stands at 7.92. In other words for every 100,000 TELA Bio shares traded daily on the market, roughly 7920 shares are currently held short.
However TELA Bio's short interest can also be evaluated against the total number of TELA Bio shares, or, against the total number of tradable TELA Bio shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case TELA Bio's short interest could be expressed as 0.01% of the outstanding shares (for every 100,000 TELA Bio shares in existence, roughly 10 shares are currently held short) or 0.0159% of the tradable shares (for every 100,000 tradable TELA Bio shares, roughly 16 shares are currently held short).
A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against TELA Bio.
Find out more about how you can short TELA Bio stock.
We're not expecting TELA Bio to pay a dividend over the next 12 months.
TELA Bio, Inc., a medical technology company, focuses on the design, development, and marketing of tissue reinforcement materials to address unmet needs in soft tissue reconstruction. The company provides a portfolio of OviTex Reinforced Tissue Matrix (OviTex) products for hernia repair and abdominal wall reconstruction; and OviTex PRS Reinforced Tissue Matrix products to address the unmet needs in plastic and reconstructive surgery, as well as OviTex for Laparoscopic and Robotic Procedures, a sterile reinforced tissue matrix derived from ovine rumen with polypropylene fiber intended to be used in laparoscopic and robotic-assisted hernia surgical repairs. It markets its products through a single direct sales force, principally in the United States. The company was founded in 2012 and is headquartered in Malvern, Pennsylvania.
Everything we know about the Home Point Capital Inc IPO, plus information on how to buy in.
Everything we know about the ALFI INC IPO, plus information on how to buy in.
Steps to owning and managing CDAY, with 24-hour and historical pricing before you buy.
Steps to owning and managing CPF, with 24-hour and historical pricing before you buy.
Steps to owning and managing CFFI, with 24-hour and historical pricing before you buy.
Steps to owning and managing BPY, with 24-hour and historical pricing before you buy.
Steps to owning and managing BANF, with 24-hour and historical pricing before you buy.
Steps to owning and managing AVDL, with 24-hour and historical pricing before you buy.
Steps to owning and managing TEAM, with 24-hour and historical pricing before you buy.
Steps to owning and managing AUDC, with 24-hour and historical pricing before you buy.